Nothing Special   »   [go: up one dir, main page]

RU2000109305A - HEALING FRACTURES USING ANALOGUES OF A PEPTIDE, SIMILAR TO A PARATHYROID HORMONE (PTN-R) - Google Patents

HEALING FRACTURES USING ANALOGUES OF A PEPTIDE, SIMILAR TO A PARATHYROID HORMONE (PTN-R)

Info

Publication number
RU2000109305A
RU2000109305A RU2000109305/14A RU2000109305A RU2000109305A RU 2000109305 A RU2000109305 A RU 2000109305A RU 2000109305/14 A RU2000109305/14 A RU 2000109305/14A RU 2000109305 A RU2000109305 A RU 2000109305A RU 2000109305 A RU2000109305 A RU 2000109305A
Authority
RU
Russia
Prior art keywords
pth
application
amino acid
analog
acid residues
Prior art date
Application number
RU2000109305/14A
Other languages
Russian (ru)
Other versions
RU2224539C2 (en
Inventor
Хенри ВИКЕРИ Брайан
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2000109305A publication Critical patent/RU2000109305A/en
Application granted granted Critical
Publication of RU2224539C2 publication Critical patent/RU2224539C2/en

Links

Images

Claims (15)

1. Способ заживления кости и репарации перелома, включающий введение пациенту, нуждающемуся в этом, эффективного количества полипептидного аналога пептида, подобного паратиреоидному гормону (РТНrР), и его солей, где остатки аминокислот в положении 22-31 этого аналога РТНrР образуют амфипатическую α-спираль.1. A method of bone healing and fracture repair, comprising administering to a patient in need thereof an effective amount of a polypeptide analog of a peptide similar to parathyroid hormone (PTH-P) and its salts, where the amino acid residues at position 22-31 of this PTH-P analog form an amphipathic α-helix . 2. Применение полипептидного аналога пептида, подобного паратиреоидному гормону (РТНrР), и его солей, где остатки аминокислот в положении 22-31 этого аналога РТНrР образуют амфипатическую α-спираль, при приготовлении лекарственного средства, предназначенного для заживления кости и репарации перелома. 2. The use of a polypeptide analog of a peptide similar to a parathyroid hormone (PTH-P) and its salts, where the amino acid residues at position 22-31 of this PTH-P analog form an amphipathic α-helix, in the preparation of a drug intended for bone healing and fracture repair. 3. Способ по п. 1 или применение по п. 2, отличающийся тем, что аналог РТНrР применяют путем назального введения. 3. The method according to p. 1 or the use of p. 2, characterized in that the analogue of PTH-R is applied by nasal administration. 4. Способ по п. 1 или применение по п. 2, дополнительно включающие местное нанесение в область перелома второго заживляющего кость агента. 4. The method according to p. 1 or the use of p. 2, further comprising topical application to the fracture region of a second bone healing agent. 5. Способ по п. 1 или применение по п. 2, отличающийся тем, что местом перелома является внутримембранозная кость. 5. The method according to p. 1 or the use according to p. 2, characterized in that the site of the fracture is the intramembranous bone. 6. Способ по п. 1 или применение по п. 2, отличающийся тем, что аналог РТНrР применяют системно. 6. The method according to p. 1 or the use of p. 2, characterized in that the analogue of PTN-R is applied systemically. 7. Способ по любому из пп. 1 или 3-6 или применение по п. 2 или по любому из пп. 3-6, отличающийся тем, что амфипатическая α-спираль имеет последовательность
Glu Leu Leu Glu Xaa Leu Leu Glu Lys Leu
где Хаа обозначает положительно заряженный остаток аминокислоты.7. The method according to any one of paragraphs. 1 or 3-6 or the use according to claim 2 or according to any one of paragraphs. 3-6, characterized in that the amphipathic α-helix has the sequence
Glu Leu Leu Glu Xaa Leu Leu Glu Lys Leu
where Haa is a positively charged amino acid residue. 8. Способ или применение по п. 7, отличающийся тем, что Хаа обозначает цистеин или гистидин. 8. The method or application of claim 7, wherein Xaa is cysteine or histidine. 9. Способ или применение по п. 8, отличающийся тем, что аналог РТНrР имеет следующую последовательность SEQ ID N4, приведенную в графической части. 9. The method or application of claim 8, wherein the PTH-P analog has the following sequence SEQ ID N4 shown in the graphic part. 10. Способ или применение по п. 7, отличающийся тем, что аналог РТНrР имеет по меньшей мере два аминокислотных остатка, связанные друг с другом через их боковые цепи. 10. The method or application of claim 7, wherein the PTH-P analog has at least two amino acid residues linked to each other via their side chains. 11. Способ или применение по п. 10, отличающийся тем, что связанные аминокислотные остатки находятся в положениях 13 и 17 или в положениях 26 и 30. 11. The method or application of claim 10, wherein the associated amino acid residues are at positions 13 and 17 or at positions 26 and 30. 12. Способ или применение по п. 11, отличающийся тем, что аминокислотный остаток в положении 17 представляет собой аспарагиновую кислоту. 12. The method or application of claim 11, wherein the amino acid residue at position 17 is aspartic acid. 13. Способ или применение по п. 12, отличающийся тем, что аналоги РТНrР имеют следующие последовательности SEQ ID N5 и N6, приведенные в графической части. 13. The method or application of claim 12, wherein the PTH-P analogs have the following sequences SEQ ID N5 and N6 shown in the graphic part. 14. Способ по любому из пп. 1 или 3-6 или применение по п. 2 или по любому из пп. 3-6, отличающийся тем, что аналог РТНrР представляет собой N-концевой укороченный фрагмент, состоящий из 30-50 аминокислотных остатков, и необязательно имеет замены в положениях 5, 13, 17, 19, 26, 30, 32 и/или 34. 14. The method according to any one of paragraphs. 1 or 3-6 or use according to claim 2 or according to any one of paragraphs. 3-6, characterized in that the PTH-P analog is an N-terminal truncated fragment consisting of 30-50 amino acid residues, and optionally has substitutions at positions 5, 13, 17, 19, 26, 30, 32 and / or 34. 15. Способ или применение по п. 14, отличающийся тем, что аналог РТНrР имеет следующую последовательность SEQ ID NN 7-12, приведенные в графической части. 15. The method or application of claim 14, wherein the PTH-P analogue has the following sequence SEQ ID NN 7-12 shown in the graphic part.
RU2000109305/15A 1997-09-09 1998-09-02 TREATING FRACTURES WITH THE HELP OF ANALOGS OF PEPTIDE BEING ANALOGOUS TO PARATHYROID HORMONE (PTHrP) RU2224539C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5832497P 1997-09-09 1997-09-09
US60/058,324 1997-09-09

Publications (2)

Publication Number Publication Date
RU2000109305A true RU2000109305A (en) 2002-02-10
RU2224539C2 RU2224539C2 (en) 2004-02-27

Family

ID=22016113

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000109305/15A RU2224539C2 (en) 1997-09-09 1998-09-02 TREATING FRACTURES WITH THE HELP OF ANALOGS OF PEPTIDE BEING ANALOGOUS TO PARATHYROID HORMONE (PTHrP)

Country Status (32)

Country Link
US (1) US6583114B2 (en)
EP (1) EP1005359B1 (en)
JP (1) JP2002509854A (en)
KR (1) KR100679778B1 (en)
CN (1) CN1210059C (en)
AR (1) AR015435A1 (en)
AT (1) ATE297754T1 (en)
AU (1) AU752925B2 (en)
BR (1) BR9812068A (en)
CA (1) CA2302255C (en)
CO (1) CO4890856A1 (en)
CZ (1) CZ298701B6 (en)
DE (1) DE69830591T2 (en)
ES (1) ES2244090T3 (en)
HK (1) HK1030753A1 (en)
HR (1) HRP20000109A2 (en)
HU (1) HU226866B1 (en)
IL (2) IL134719A0 (en)
MA (1) MA26545A1 (en)
MY (1) MY121291A (en)
NO (1) NO323740B1 (en)
NZ (1) NZ502970A (en)
PE (1) PE117399A1 (en)
PL (1) PL195703B1 (en)
RS (1) RS49707B (en)
RU (1) RU2224539C2 (en)
SA (1) SA98190565B1 (en)
TR (1) TR200000649T2 (en)
TW (1) TW552139B (en)
UY (1) UY25172A1 (en)
WO (1) WO1999012561A2 (en)
ZA (1) ZA988030B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1136076A1 (en) * 1998-08-19 2001-09-26 Eli Lilly And Company Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (en) 1998-08-19 2004-01-07 Lilly Co Eli USE OF PARTIROID HORMONES TO PREPARE MEDICINES TO REDUCE THE RISK OF VERTEBRAL OR NON-VERTEBRAL OSEAS FRACTURES IN HUMAN BEINGS WITH RISK OF SUFFERING OR WHO HAVE OSTEOPOROSIS
EP1769804B1 (en) * 1998-08-19 2012-09-19 Eli Lilly And Company hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
CA2245903A1 (en) * 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2364948C (en) 1999-03-05 2011-04-26 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6393328B1 (en) * 2000-05-08 2002-05-21 International Rehabilitative Sciences, Inc. Multi-functional portable electro-medical device
US6560487B1 (en) * 2000-05-08 2003-05-06 International Rehabilitative Sciences, Inc. Electro-medical device for use with biologics
US6675048B2 (en) * 2000-05-08 2004-01-06 International Rehabilitative Sciences, Inc. Electro-medical device for use with biologics
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
AU2003272814A1 (en) 2003-10-02 2005-05-19 Ibrahim Al-Habdan Peptide for promoting healing of fractures
EP1804820A4 (en) * 2004-10-08 2009-12-02 Transition Therapeutics Inc Vasoactive intestinal polypeptide pharmaceuticals
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20090022684A1 (en) * 2006-05-09 2009-01-22 Paul Morley Methods for hematopoietic stimulation
SG175580A1 (en) 2006-10-03 2011-11-28 Radius Health Inc Method of drug delivery for bone anabolic protein
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
JP5564167B2 (en) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 Bitter taste masking agent and method for reducing bitterness
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
CN104146961B (en) * 2014-07-04 2018-02-27 深圳职业技术学院 A kind of film evaporation method prepares the method for carrying cell factor and SPP1 microballoon
EP3294065A4 (en) 2015-04-29 2019-03-20 Radius Pharmaceuticals, Inc. Methods of treating cancer
CN108025042A (en) * 2015-07-06 2018-05-11 董正欣 The new formulation of PTHrP analogs
WO2017184355A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
DK3565542T3 (en) 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc POLYMORPHIC FORMS OF RAD1901-2HCL
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
MX2020013713A (en) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl.
MX2022002979A (en) * 2019-09-12 2022-06-16 Radius Health Inc Methods of improving spinal fusion with abaloparatide.
CN112646042A (en) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 Active polypeptide compounds
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935738A1 (en) * 1989-10-27 1991-05-08 Forssmann Wolf Georg DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) * 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
CN1070500C (en) * 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU8002994A (en) * 1993-10-27 1995-05-22 Chugai Seiyaku Kabushiki Kaisha Cure accelerator in chondroplasty
JPH08310965A (en) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd Coalition promoter
US5717062A (en) * 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone

Similar Documents

Publication Publication Date Title
RU2000109305A (en) HEALING FRACTURES USING ANALOGUES OF A PEPTIDE, SIMILAR TO A PARATHYROID HORMONE (PTN-R)
CA2302255A1 (en) Fracture healing using pthrp analogs
JP2002509854A5 (en)
ES2207680T3 (en) ANALOGS OF THE PARTIROID HORMONE.
ES2258286T3 (en) PTHRP ANALOGS
JP4620309B2 (en) Parathyroid hormone analogs for the treatment of osteoporosis
US6921750B2 (en) Analogs of parathyroid hormone
JP2009057386A (en) Parathyroid hormone analogues for treatment of osteoporosis
HK1040738A1 (en) Human parathyroid hormone modifications, preparation and use
ATE377026T1 (en) TREATMENT OF OBESITY
HUP0401441A2 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
JP2015503512A (en) Novel GH-RH analogs with potent agonist activity
AU2004265280A1 (en) Antagonistic analogs of GH-RH (2003)
JP2004538320A5 (en)
TH50339B (en) Healing fractures of the bone using analogue of PTHrP.
KR950704358A (en) Cathepsin L specific inhibitory polypeptide
TH40579A (en) Healing fractures of the bone using analogue of PTHrP.
CN1916025B (en) Analogs of parathyroid hormone
SI9300595B (en) Peptides with organo-protective activity, procedure for their preparation and their therapeutical use
TH26711A (en) "Homone secretion of growth factor"